DMYD-B:STO
Diamyd Medical AB
SEKÂ 1.03
arrow_downward
-1.72%(-0.018) 1D
Okt 14, 5:21:24 PM GMT+2 · SEK
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa DMYD-B...
Buksan
SEKÂ 1.05
Mataas
SEKÂ 1.07
Mababa
SEKÂ 1.01
Mkt. cap
155.73M
Avg. na dami
831.77K
Dami
172.28K
Mataas nang 52-wk
SEKÂ 17.88
Mababa nang 52-wk
SEKÂ 0.90
EPS
-SEKÂ 1.76
Mga natitirang share
134.00M
Bilang ng mga empleyado
42
Buksan
SEKÂ 1.05
Mataas
SEKÂ 1.07
Mababa
SEKÂ 1.01
Mkt. cap
155.73M
Avg. na dami
831.77K
Dami
172.28K
Mataas nang 52-wk
SEKÂ 17.88
Mababa nang 52-wk
SEKÂ 0.90
EPS
-SEKÂ 1.76
Mga natitirang share
134.00M
Bilang ng mga empleyado
42
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
investingLive
·
11 oras ang nakalipas
S&P 500 decline extends to 100 points with tech hit particularly hard
Bloomberg.com
·
8 oras ang nakalipas
S&P 500 Ends Longest Streak of Calm Since 2020 as AI Trade Sinks
MarketWatch
·
1 buwan ang nakalipas
The S&P 500 keeps climbing on days when stocks broadly struggle. Here’s what’s going on.
Reuters
·
1 buwan ang nakalipas
S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Tungkol sa Diamyd Medical AB